Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

876
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
876
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
Hematopoiesis01:21

Hematopoiesis

8.7K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.7K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

3.1K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.1K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating carbohydrate antigen Ca10H predicts favorable prognosis in colorectal cancer.

Scientific reports·2026
Same author

Metabolic support of trained immune responses in myeloid cells.

eLife·2026
Same author

Elevated sCD25 predicts early infection in patients with major burns.

Critical care (London, England)·2026
Same author

HIF-1α and HIF-2α differentially regulate alveolar macrophage maturation and function.

Cell reports·2026
Same author

Mitochondrial complex I activity promotes antigen cross-presentation in dendritic cells.

Science immunology·2026
Same author

Polymeric immunoglobulin receptor deficiency attenuates experimental atherosclerosis.

Frontiers in immunology·2026

Related Experiment Video

Updated: Jan 14, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

879

SHIPi improves hematologic recovery after chemotherapy.

Sandra Fernandes1, Chiara Pedicone1, Otto M Dungan2

  • 1Department of Microbiology & Immunology, SUNY Upstate Medical University, Syracuse, NY, USA.

Molecular Medicine (Cambridge, Mass.)
|October 22, 2025
PubMed
Summary

Small molecule inhibitors of SHIP1 (somatic hyperplasia inhibitor 1) can boost the body's natural production of growth factors, improving recovery after chemotherapy and increasing survival rates.

Keywords:
5-FUA32Candida albicansChemotherapyK161NeutrophilsSHIP1SHIPi

More Related Videos

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.7K
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

13.9K

Related Experiment Videos

Last Updated: Jan 14, 2026

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells
05:32

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

879
Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

1.7K
Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

13.9K

Area of Science:

  • Hematology
  • Immunology
  • Pharmacology

Background:

  • Recombinant growth factors improve hematopoietic function post-chemotherapy, yet life-threatening hematologic and immune complications persist.
  • Existing treatments face challenges in fully mitigating chemotherapy-induced complications.

Purpose of the Study:

  • To investigate the potential of pan-SHIP inhibitors (pan-SHIPi) and novel SHIP1-selective inhibitors to enhance endogenous growth factor production and improve outcomes after chemotherapy.
  • To evaluate the efficacy of these inhibitors in promoting hematologic recovery and increasing host survival.

Main Methods:

  • Administration of pan-SHIPi compounds and a novel SHIP1-selective inhibitor (A32) to mice.
  • Assessment of endogenous G-CSF (granulocyte-colony stimulating factor) and TPO (thrombopoietin) production in vivo.
  • Evaluation of host survival after a lethal fungal challenge.
  • Analysis of granulopoiesis and neutrophil count recovery post-chemotherapy.

Main Results:

  • Pan-SHIPi compounds induced endogenous G-CSF and TPO production, increasing host survival after lethal fungal challenge.
  • Pan-SHIPi compounds promoted granulopoiesis and accelerated neutrophil count recovery in mice post-chemotherapy.
  • The novel SHIP1-selective inhibitor A32 also increased steady-state production of G-CSF and TPO.

Conclusions:

  • Small molecule inhibitors of SHIP1 effectively promote hematologic recovery after myeloablative chemotherapy.
  • SHIP1 inhibitors represent a novel strategy for inducing endogenous production of multiple growth factors crucial for hematologic recovery.